Clinical Trial Update: Safety and Immunogenicity of Prime-Boost Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-002) [Phase 1]

View source ↗

Summary

Phase 1 trial reporting safety and immunogenicity of prime-boost VSV Ebola vaccine (V920-002) in healthy adults; results completed and posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease

Drugs mentioned

• V920 (Vesicular Stomatitis Virus Ebola vaccine) (rVSV-EBOV vaccine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Ebola Viruses | Phase 1 | Status: COMPLETED | Results posted: 2019-07-12